Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

GSK plc (NYSE:GSK) – GSK agreed to pay up to $2.2 billion to settle 93% of U.S. lawsuits related to Zantac, alleging the drug caused cancer. The settlement, announced Wednesday, was lower than ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the ...

Over-the counter eye drops can relieve eye issues like allergies, redness, watery eyes, itchiness and dryness-- including dry contact lenses. Picking the right one to use on the market can be ...

GSK plc (GSK.L) reported that its third quarter profit before tax dropped to 64 million pounds from 1.79 billion pounds in the ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...